RxDoctor Payments Data

Walton Joyner, MD

Ophthalmology · Raleigh, NCNPI 1851376164

Payments from drug & device makers

$1,813in general payments, 2019–2025

Across 58 payments — averaging $31.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$499
  • Alcon$253
  • Tarsus Pharmaceuticals, Inc.$221
  • Amgen$207
  • Oyster Point Pharma, Inc.$144
  • Bausch & Lomb Americas Inc.$139
  • plus $351 from 8 others

What the payments were for

  • Food & beverage$1,813100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,813 in reported general payments places this provider in the 50th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$125,498
Medicare patients
743
Services billed
1,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine29$40,508
LumiganBimatoprost28$15,666
MieboPerfluorohexyloctane/Pf16$13,070
XiidraLifitegrast15$12,944
VyzultaLatanoprostene Bunod20$9,677
Cyclosporine12$8,891
RocklatanNetarsudil Mesylat/Latanoprost17$5,645
Alphagan PBrimonidine Tartrate19$4,470
Brimonidine Tartrate27$3,715
Latanoprost230$3,361
SimbrinzaBrinzolamide/Brimonidine Tart15$3,344
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$2,973
Prednisolone Acetate86$2,587
Doxycycline Hyclate54$572
Timolol Maleate46$502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$499$60,64476 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$139$35,69251 claims
Aerie Pharmaceuticals, Inc.Rocklatan$122$5,64517 claims
AlconSimbrinza$253$3,34415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →